Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.55 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.55 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.55 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.55 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.55 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.55 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.55 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.55 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.55 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.55 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.55 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.55 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.55 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.55 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.55 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.55 |
| ▸ | KCNQ3 known ✓ | O43525 | 1/20 | 0.44 |
| ▸ | KCNQ2 known ✓ | O43526 | 1/20 | 0.44 |
| ▸ | P4HA1 | P13674 | 3/20 | 0.59 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29723813 | 0.98 | P4HA1 (0.61) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL29646483 | 0.98 | P4HA1 (0.61) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL646556 | 0.98 | P4HA1 (0.61) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL30448953 | 0.98 | P4HA1 (0.61) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL27594193 | 0.82 | RXFP1 (0.53) | P4HA1P4HTMMIFGABRPGABRD | |
| SCHEMBL2042090 | 0.82 | BCL2L1 (0.59) | HSD17B10TP53TSHRBCL2L1BAD | |
| SCHEMBL29788190 | 0.82 | BCL2L1 (0.59) | HSD17B10TP53TSHRBCL2L1BAD | |
| Hydrochloric Acid SCHEMBL5009748 | 0.81 | NNMT (0.59) | L3MBTL1EPHX2KCNQ3KCNQ2 | |
| SCHEMBL29117149 | 0.80 | HCAR3 (0.54) | P4HA1P4HTMNAPRTHCAR3MAPT | |
| SCHEMBL2514243 | 0.78 | KCNQ3 (0.44) | P4HA1P4HTMMIFGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022222963-A1 | IMIDAZOLE-CONTAINING CONDENSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | 长春金赛药业有限责任公司 | 2022-10-27 | — | — | WO | disclosed |
| EP-2421871-B1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-8304556-B2 | Thiazolyl-dihydro-indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8288379-B2 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| EP-2421871-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2012-02-29 | — | — | EP | disclosed |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| EP-2280982-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | Boehringer Ingelheim International GmbH (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2010122071-A1 | THIA-TRIAZA-CYCLOPENTAZULENES AS PI3-KINASES INHIBITORS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2009112565-A1 | THIAZOLYL-DIHYDRO-INDAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108567-A1 | Thiazolyl-Dihydro-Indazoles | MKI67, CYP11B1, IGF1R | GABRP 4659/4885GABRD 4623/4885GABRA1 4142/4885 |
| US-20110112087-A1 | Thia-triaza-cyclopentazulenes | CCNA1, MKI67, CCNT1 | GABRP 4310/4885GABRD 4002/4885GABRA1 1771/4885 |
| US-20110118208-A1 | Thiazolyl-Dihydro-Indazoles | MKI67, CYP11B1, IGF1R | GABRP 4659/4885GABRD 4623/4885GABRA1 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.